Publication:

Update on the Management of Aspirin-Exacerbated Respiratory Disease

Loading...
Thumbnail Image

Date

2016

Journal Title

Journal ISSN

Volume Title

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Buchheit, Kathleen M., and Tanya M. Laidlaw. 2016. “Update on the Management of Aspirin-Exacerbated Respiratory Disease.” Allergy, Asthma & Immunology Research 8 (4): 298-304. doi:10.4168/aair.2016.8.4.298. http://dx.doi.org/10.4168/aair.2016.8.4.298.

Abstract

Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.

Description

Research Data

Keywords

Aspirin-exacerbated respiratory disease, Samter's triad, nasal polyps, aspirin desensitization

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories